Loop Capital analyst Alan Gould downgrades Paramount Global (NASDAQ:PARA) from Hold to Sell and lowers the price target from $30 to $14.
Veracyte, Inc. Announces Study Published In JNCI Cancer Spectrum Demonstrates Real-World Utility Of Co’s Decipher Prostate Genomic Classifier In Prostate Cancer Treatment
Clinical utility study findings based on analysis of the National Cancer Institute's SEER database
Veracyte, Inc. (NASDAQ:VCYT) announced the publication of a large, real-world study reinforcing the Decipher
